A COMPARATIVE STUDY OF CARDIOVASCULAR TOXICITY OF EPIRUBICIN AND DOXORUBICIN IN PATIENTS WITH BREAST CANCER.

Unlabelled: Patients with breast cancer (BC) are at high risk of cardiotoxicity (CT) due to combination of anticancer treatment.Cardio-vascular (СV) complications lead to the delay or discontinuation of anticancer therapy, which significantlyworsens the prognosis. Anthracyclines (AC) are the main drugs included in most anticancer treatment regimens.

RISK SCORE MODEL FOR PREDICTING CARDIOTOXICITY IN BREAST CANCER: DIAGNOSTIC VALUE OF HIGH-SENSITIVITY CARDIAC TROPONIN T.

Unlabelled: Cardiovascular diseases are the second leading cause of death among breast cancer (BC) patients. Prediction of cardiovascular toxicity (CT) is an important part of the successful treatment and survival of patients.

Objective: to develop a risk score model for cardiovascular toxicity (CT) predicting, based on cardiovascular risk factors (RFs), RFs associated with cancer therapy, and troponin levels.

NEW DATA ON HISTOGENESIS AND HISTOLOGICAL STRUCTURE OF LUNG CANCER.

Background: Lung cancer (LC) is one of the most common malignant neoplasms in men around the world, which poses a number of important challenges for scientists.

Aim: To analyze the histogenesis, features of the histological structure, and growth of LC.

Materials And Methods: The surgical material of 81 patients with LC was studied.

Breast cancer relapses considering molecular biological characteristics.

We aimed to analyze the frequency of breast cancer relapses and their relationship with molecular and biological tumor characteristics. We studied 6,136 breast cancer patients, including 146 with relapses (Group 1) and 455 without relapses (Group 2). We divided the patients based on age, menstrual function, disease stage, histology form and grade, and molecular-biological subtype.

Main factors determining the use of free MS-TRAM and DIEP flaps and comparing the results of breast reconstruction.

This study aimed to compare the results of free MS-TRAM and DIEP-flap based on the volume of the transplant and the unique characteristics of blood flow in the tissues. The study included 83 patients, 42 in the MS-TRAM-flap reconstruction group and 41 in the DIEP-flap breast reconstruction group. In the MS-TRAM-flap group, 35 patients received delayed reconstruction, and 7 received one-stage breast reconstruction, including one case of bilateral transplantation.

Features of VEGF and IL-6 expression in patients with inflammatory breast cancer considering molecular-biological characteristics.

Expression of pro-malignant factors (VEGF) and cytokines like inflammatory components support breast cancer development. We examined 46 patients with stage IIIB inflammatory breast cancer (IBC) and 24 with stage IIA-IIIB breast cancer (BC) without secondary edema. Hormone receptors, Her-2/neu, Ki-67 index, VEGF, and IL-6, were determined for all patients before and after neoadjuvant treatment.

CARDIOTOXICITY IN BREAST CANCER PATIENTS: RELATIONSHIP OF HS-TROPONIN T CHANGES AND HEART FUNCTION IN CANCER TREATMENT.

Unlabelled: Breast cancer patients (BC) have a high risk of cardiotoxicity (CT) due to a combination of cancer treatments.Cardiovascular (CV) complications lead to delay or withdrawal of BC therapy and worsen the survival. Therefore, it isimportant to detect CT at the early stages before the occurrence of cardiac dysfunction and heart failure (HF) signs.

Phosphorus metabolism disorders in erythrocytes and lymphocytes among patients with inflammatory breast cancer, infiltrative stomach and colorectal cancer.

Energy and plastic potential dysfunction of erythrocytes and lymphocytes among people with inflammatory breast cancer, infiltrative stomach cancer, and infiltrative colon cancer is characterized by a more aggressive clinical course and poor prognosis. We explored the features of energy metabolism and phosphorus metabolism disorders in the erythrocytes and lymphocytes of patients with inflammatory breast cancer, infiltrative stomach cancer, and infiltrative colon cancer as a predicting factor in the course of the disease. 49 people were examined; the 1 group had infiltrative stomach cancer (n=17); the 2 group had infiltrative colon cancer (n=11); the 3 group had inflammatory breast cancer (n=21).

Delayed breast reconstruction with tram-flap and various modifications after radical mastectomy.

This study describes the experience of radical mastectomies with simultaneous breast reconstruction using TRAM flap in patients with inflammatory breast cancer. The study aimed to evaluate the effectiveness of primary breast reconstruction using the TRAM-flap procedure in patients with an inflammatory form of breast cancer. Our work is associated with some deviation from generally accepted standards: delayed breast reconstruction after radical mastectomy for inflammatory breast cancer.

CARDIOTOXICITY RISK PREDICTION IN BREAST CANCER PATIENTS.

Unlabelled: Breast cancer patients receive combined antitumor treatment (surgery, chemotherapy, targeted drugs and radia-tion), so they are considered to be the patients with potentially high risk of cardiotoxicity (CT). Risk stratificationof cardiovascular complications before the beginning and during the cancer treatment is an important issue.

Objective: to develop a CT risk model score taking into account cardiological, oncological and individual risks.

Efficacy of Combination Neoadjuvant Chemotherapy and Regional Inductive Moderate Hyperthermia in the Treatment of Patients With Locally Advanced Breast Cancer.

Purpose: To evaluate the efficacy of neoadjuvant chemotherapy in combination with regional inductive moderate hyperthermia for patients with locally advanced breast cancer.

Patients And Methods: 200 patients with stage IIB-IIIA breast cancer received neoadjuvant chemotherapy (control group, n = 97) or chemotherapy combined with hyperthermia (experimental group, n = 103). Inductive hyperthermia was set at 27.

Predictive factors of pathological response to neoadjuvant chemotherapy in patients with breast cancer.

Purpose: To identify predictive factors connected with pathologic response in patients with breast cancer (BC) having received neoadjuvant chemotherapy (NACT).

Methods: 49 patients with BC were investigated before and after treatment in this prospective research. Different chemotherapy regimes were administered.

Are CD44/CD24 cells the assumed cancer stem cells in breast cancer?

Unlabelled: Identification and characterization of the population of cancer stem cells (CSC) depends on several cellular markers, which combination is specific for the phenotype of CSC in the corresponding tumor. Several markers of CSC have already been identified in breast cancer (BC), but there are no universal indicators that could specifically identify the CSC in BC.

Aims: To determine the validation of the CSC model for cell surface markers such as CD44 and CD24 and their clinical significance.

The frequency of BRCA1 founder mutation c.5266dupC (5382insC) in breast cancer patients from Ukraine.

Germ-line mutations in several genes, such as BRCA1 and BRCA2, are known to increase the risk of breast cancer. These heritable mutations are unequally represented among populations with different ethnic background due to founder effects and thereby contribute to differences in breast cancer rates in different populations. The BRCA1 mutation c.

[Systemic enzymotherapy as a method of prophylaxis of postradiation complications in oncological patients].

Set out in the paper are results of treatment of those patients with carcinoma of the lung, uterine cervix, hysterocarcinoma, breast cancer, malignant thymomas, malignant non-Hodgkin's lymphomas, and lymphogranulematosis having been administered combined, chemoradiation or radiation treatments against the background of a complex of accompanying therapy involving systemic enzymotherapy. Polyenzymic drugs were found to be capable of improving results of treatment of acute radiation reactions and preventing postradiation fibrous changes in the lungs, skin, fatty tissue, soft tissue, liver, kidneys. Thus, systemic enzymotherapy is capable of improving the quality of life and results of treatment of oncological patients.

[Enhancement of efficacy of neoadjuvant polychemotherapy in combined treatment of lung cancer].

It is not infrequently that the known preoperative chemotherapy options come to be not very effective in the treatment of patients with pulmonary cancer by reason of a fraction of chemoresistant tumour cells. To enhance effectiveness of treatment we attempted preoperative thermochemotherapy. As many as 62 patients with pulmonary cancer were exposed preoperatively to a 40-minute r.

[Application of systemic enzyme therapy in combined treatment of patients with pulmonary cancer and malignant thymoma].

The systemic enzymotherapy using Wobe-Mugos E in the combined treatment of 32 patients with pulmonary cancer and of 21 patients with malignant thymoma was applied. After the chemotherapy and radiotherapy conduction the reduction of the postoperative septic-purulent complications, the pneumofibrosis occurrence prophylaxis was noted.

[Systemic enzyme therapy with the preparation Wobe-Mugos E in the combined treatment of lung cancer patients].

A total of 44 patients with lung carcinoma underwent combined treatment involving systemic enzyme therapy with Wobe-Mugos E. In conducting radio- and polychemotherapy, the above enzyme therapy did not complicate the postoperative course, with the pyo-septic complications having gotten reduced, the origination of pneumofibroses prevented.

[Nonspecific active immunotherapy in surgical treatment of patients with pulmonary cancer].

Application of nonspecific active immunotherapy in the treatment of 59 radically operated patients with pulmonary cancer had permitted in brief period of time to restore quantitative and functional indexes of cellular link of immunity, had promoted noncomplicated course of postoperative period, the reduction of the postoperative complications frequency and improvement of late follow-up results of surgical treatment of the patients in the absence of metastases in regional lymphatic nodes.

[Radioimmunologic analysis of trypsin and C-peptide tumor markers for evaluation of treatment efficiency in patients with pancreatic and Vater's ampulla cancer].

A radioimmunological analysis of the changes in concentration of tumour markers CA 19-9, REA, beta 2-microglobulin, trypsin and C-peptide was carried out in 53 patients with pancreatic cancer and in 14 patients with cancer of the major duodenal papilla before and 7-10 days after the treatment. A control group was comprised of 116 volunteers. The levels of the tumour markers decreased after the combined use of remote radiotherapy and pancreaticoduodenal resection (PDR).

[Early relaparotomies after surgical treatment of cancer of the stomach].

Based on the observation of 40 patients the authors consider that the greatest amount of postoperative complications in patients with gastric cancer make their appearance after reconstructive and palliative gastrectomies and combined operative interventions. Timely relaparotomy allowed saving 37.5% of the patients who had such complications as incompetence of anastomosis sutures, pancreanecrosis, peritonitis, intraabdominal abscesses.